Biotech Values

[DewDiligence]

Solodyn is the correct answer—well done! According to MRX, Ranbaxy (not Sandoz) holds first-filer status on the 105mg dose, so there are three (not four) first-filer companies for the various non-legacy doses.

This is the status of all eight dosage strengths:

45mg: legacy dose; multiple generics starting Nov 2011*
55mg: Lupin has first-filer status; litigation pending
65mg: Teva has first-filer status; case settled
80mg: Ranbaxy has first-filer status; case settled
90mg: legacy dose; multiple generics starting Nov 2011*
105mg: Ranbaxy has first-filer status; case settled
115mg: Teva has first-filer status; case settled
135mg: legacy dose; multiple generics starting Nov 2011*

*Some generic use at these doses is occurring now due to product remaining from prior at-risk launches.